Kolexia
Jouannaud Christelle Oncologie médicale
Jouannaud Christelle
Oncologie médicale
Institut Godinot
Reims, France
148 Activités
18 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du sein triple-négatives Fatigue Récidive tumorale locale Tumeur du sein de l'homme Seconde tumeur primitive Cardiopathies Hypertension artérielle

Collaborateurs

Voir plus
Levy Christelle
Levy Christelle
Centre François-Baclesse, Caen, France
Mouret-Reynier Marie-Ange
Mouret-Reynier Marie-Ange
Centre Jean-Perrin, Clermont-Ferrand, France
Petit Thierry
Petit Thierry
Centre Paul Strauss, Strasbourg, France
Cottu Paul-Henri
Cottu Paul-Henri
Clcc Institut Curie, Paris, France

Industries

Voir plus
Pfizer
6 collaboration(s)
Dernière en 2023
Lilly
5 collaboration(s)
Dernière en 2023
AstraZeneca
3 collaboration(s)
Dernière en 2022
Seagen
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial.
Breast cancer research and treatment   07 mars 2024
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence
Essai Clinique (Lilly)   29 février 2024
ETIC-LM: Multicentric Single Arm Phase II Study Evaluating the Efficacy of Association of Tucatinib, Capecitabine and Intra-CSF Trastuzumab in HER2 Amplified Breast Cancer Patients With Leptomeningeal Metastases
Essai Clinique (Seagen)   02 février 2024
GrannyFit: Digital Phenotyping (Physical Activity, Sleep) in Women Over 70 Years of Age Treated for Breast Cancer With Any Type of Treatment
Essai Clinique (Institut Curie)   26 janvier 2024
NeoFit: Digital Phenotyping (Physical Activity, Heart Rate, Sleep) in Young Breast Cancer Patients Treated With Neoadjuvant Chemotherapy
Essai Clinique (Institut Curie)   26 janvier 2024
NeoTOP: Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer
Essai Clinique (Unicancer)   06 décembre 2023
Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
The oncologist   11 octobre 2023
255P Prognostic stratification capacity of the CPS+EG scoring system in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
CN15 Real-life clinical and organizational evaluation of telemonitoring and assisted telemonitoring in more than 1500 cancer patients
Abstract Book of the ESMO Congress 2023, 20 - 24 October 2023.   01 octobre 2023
InTTercePT: Treatment With Tucatinib in Addition to Pertuzumab and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer After Local Therapy of Isolated Brain Progression
Essai Clinique (Seagen)   21 septembre 2023